Cholangiocarcinoma (CCA) is a rare tumor comprising approximately 3% of gastrointestinal tumors with an overall incidence of less than 2/100 000. It is the second most common primary hepatic malignancy following hepatocellular carcinoma (HCC). 1,2 CCA incidence has been increasing globally during the last decades, where its incidence increases with age. 3 According to the anatomic location, CCA is classified into intrahepatic (IH-CCA) and extrahepatic (EH-CCA) where the later accounts for 80%-90% of all cases. 4 The commonest risk factors for CCA are primary sclerosing cholangitis (PSC), 5 chronic liver disease (including chronic viral hepatitis B and C), 6 and intrahepatic stones (hepatolithiasis). 7 CCA patients remain clinically silent until the advanced stages of the disease. The common clinical feature of EH-CCA is biliary obstruction resulting in painless jaundice, while IH-CCA presents in most cases